



71-0384

E.I. DU PONT DE NEMOURS & CO. (INC.)
MEDICAL PRODUCTS DEPARTMENT

December 7, 1990

United States Nuclear Regulatory Commission
Attn: Charles E. MacDonald, Chief
Transportation Branch
Division of Safeguards and Transportation, NMSS
Washington, D.C. 20555

Reference: QA Program Approval Number 0384

Dear Mr. MacDonald:

This is a request for an amendment to the the above-referenced Quality Assurance Program Approval for Radioactive Material Packages to reflect a new business name.

On January 1, 1991, a new company will be officially formed by a Joint Venture between the two major corporations, Du Pont and Merck. The name of our company will be changing from Du Pont to the Du Pont Merck Pharmaceutical Company.

Therefore, effective January 1, 1991, the name and address of our company should be listed on the approval as:

Du Pont Merck Pharmaceutical Company
331 Treble Cove Road
North Billerica, Massachusetts 01862

Due to this change in the company name, a revised version of the Quality Assurance Program has been written and is enclosed for your review. Once approved, the scope of the revised program will cover only the operations at the Billerica address. A request for a QA Program Approval for the operations at the Du Pont facility at 549 Albany Street, Boston MA, previously a part of approval number 0384, will be submitted to you under separate cover.

I have enclosed a check in the amount of \$180.00 in payment of the amendment processing fee as specified for License Category 10B in the regulations of Title 10 CFR Part 170, Section 170.31.

Please contact me if you require any additional information.

Sincerely,

Francis E. Roy Jr.

Francis E. Roy Jr.
Health Physicist
Telephone: (508) 671-8242

*Rec'd
W/CC #
395-4205P
for \$180.00*

MEDICAL PRODUCTS DEPARTMENT

331 Treble Cove Road, No. Billerica, MA 01862 Telephone 508-667-9531

9012110073 901207
PDR ADOCK 07100384
C PDC

NT021